12:00 AM
 | 
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Canmab biosimilar trastuzumab regulatory update

Biocon said the Drugs Controller General of India approved its biosimilar of Herceptin trastuzumab to treat HER2-positive, metastatic breast cancer. The company plans to launch the product in India...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >